What is Sofregen Medical?
Sofregen Medical Inc. is at the forefront of developing and providing advanced natural biomaterials, with a core focus on purified silk protein. These innovative materials are designed to enhance surgical outcomes by facilitating soft tissue regeneration. The company's product portfolio includes solutions like the Silk Voice Injectable Implant, aimed at improving aesthetic procedures such as vocal fold medialization. By leveraging the science of silk protein, Sofregen Medical empowers skilled medical aesthetic practitioners, setting new benchmarks in the field of aesthetic medicine and regenerative therapies.
How much funding has Sofregen Medical raised?
Sofregen Medical has raised a total of $19.4M across 4 funding rounds:
Angel/Seed
$1.6M
Series A
$9.7M
Series B
$8M
Debt
$150K
Angel/Seed (2014): $1.6M, investors not publicly disclosed
Series A (2016): $9.7M led by Polaris Partners
Series B (2019): $8M supported by Anzu Partners
Debt (2020): $150K featuring PPP
Key Investors in Sofregen Medical
Anzu Partners
Anzu Partners is an investment firm focused on breakthrough technologies in clean tech, industrial, and life sciences sectors. They provide expertise in business development and market positioning to accelerate growth for innovative companies.
Polaris Partners
Polaris Partners is a venture capital firm specializing in backing transformational companies in the biotech and healthcare sectors, offering coaching and resources for growth.
What's next for Sofregen Medical?
The recent major strategic investment in Sofregen Medical signals a pivotal phase for the company, likely enabling accelerated product development, expanded market penetration, and further research into the therapeutic applications of silk protein. This capital infusion is expected to bolster their efforts in scaling operations and solidifying their position as a leader in biomaterial innovation for aesthetic and reconstructive medicine. The company's commitment to advancing its product pipeline suggests a strategic focus on commercialization and broader adoption within the medical community.
See full Sofregen Medical company page
